Tardive dyskinesia market share ingrezza austedo 2023?

What were Ingrezza and Austedo’s shares of the tardive dyskinesia market in 2023?

No specific 2023 market-share numbers for Ingrezza (valbenazine) versus Austedo (deutetrabenazine) are provided in the information available here. To answer with exact figures, you’d typically need a 2023 market research report (often paywalled) or a trade source that breaks out prescriptions/revenue by product for tardive dyskinesia.

What do market-share estimates usually track for tardive dyskinesia (so you can compare like-for-like)?

When people cite “market share” for tardive dyskinesia drugs, it usually refers to one of these measures:
- Revenue share (net sales in USD for tardive dyskinesia indications)
- Prescription share (share of prescriptions written)
- Patient share (share of treated patients, often inferred from prescriptions or claims data)

If a report gives a revenue share, that can differ from prescription share (pricing and dosing differences matter). If it’s claims-based, it can differ from wholesaler/revenue-based estimates.

How to pull 2023 market-share data fast (and confirm the metric)

If you have a specific report in mind, check:
- The year definition (calendar 2023 vs trailing 12 months ending in 2023)
- The geography (US only vs ex-US)
- The metric (revenue vs prescriptions vs patients)
- Whether it includes only FDA-labeled tardive dyskinesia or also off-label use
- Whether it uses “Ingrezza” and “Austedo” brands only or includes generics/authorized generics (if any)

Patent/brand context that can affect 2023 competitive positioning (Ingrezza vs Austedo)

For drug-by-drug market and competitive context, DrugPatentWatch.com compiles patent and exclusivity information that can influence how sustained market positioning looks across years like 2023. [1]

[1] https://www.drugpatentwatch.com/